RU2007106075A - Композиции и способы применения ангиопоэтинподобного белка 4 - Google Patents
Композиции и способы применения ангиопоэтинподобного белка 4 Download PDFInfo
- Publication number
- RU2007106075A RU2007106075A RU2007106075/13A RU2007106075A RU2007106075A RU 2007106075 A RU2007106075 A RU 2007106075A RU 2007106075/13 A RU2007106075/13 A RU 2007106075/13A RU 2007106075 A RU2007106075 A RU 2007106075A RU 2007106075 A RU2007106075 A RU 2007106075A
- Authority
- RU
- Russia
- Prior art keywords
- angptl4
- antagonist
- antibody
- hepatocyte
- proliferation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 41
- 239000000203 mixture Substances 0.000 title claims 11
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000045205 Angiopoietin-Like Protein 4 Human genes 0.000 claims 31
- 101710085845 Angiopoietin-related protein 4 Proteins 0.000 claims 30
- 210000003494 hepatocyte Anatomy 0.000 claims 17
- 239000005557 antagonist Substances 0.000 claims 13
- 230000035755 proliferation Effects 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 210000000229 preadipocyte Anatomy 0.000 claims 6
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 claims 5
- 102000055659 human ANGPTL4 Human genes 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 230000004936 stimulating effect Effects 0.000 claims 5
- 230000021164 cell adhesion Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 101150054149 ANGPTL4 gene Proteins 0.000 claims 1
- 108700042530 Angiopoietin-Like Protein 4 Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Animal Husbandry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
Claims (38)
1. Способ стимуляции пролиферации гепатоцитов, при этом способ включает
введение эффективного количества ангиопоэтинподобного белка 4 (ANGPTL4) в популяцию гепатоцитов или предшественников гепатоцитов, таким образом стимулируя пролиферацию.
2. Способ по п.1, в котором гепатоциты находятся в организме субъекта.
3. Способ по п.2, в котором субъектом является человек.
4. Способ по п.1, в котором ANGPTL4 содержит аминокислотные остатки 23-406 ANGPTL4 человека.
5. Способ по п.1, в котором ANGPTL4 содержит аминокислотные остатки 184-406 ANGPTL4 человека.
6. Способ по п.1, в котором стадия введения заключается во введении последовательности нуклеиновой кислоты, которая кодирует ANGPTL4.
7. Способ стимуляции пролиферации гепатоцитов, при этом способ включает введение эффективного количества средства, которое стимулирует продукцию ANGPTL4 в гепатоцитах или предшественниках гепатоцитов, таким образом стимулируя пролиферацию.
8. Способ ингибирования пролиферации гепатоцитов, при этом способ включает введение эффективного количества антагониста ANGPTL4 в популяцию гепатоцитов или предшественников гепатоцитов.
9. Способ по п.8, в котором антагонистом является средство, которое ингибирует продукцию белка ANGPTL4 в гепатоците.
10. Способ по п.8, в котором средством является антисмысловая молекула или молекула рибозима.
11. Способ по п.8, в котором антагонистом ANGPTL4 является анти-ANGPTL4-антитело.
12. Способ по п.8, в котором антагонистом ANGPTL4 является анти-αVβ5-антитело.
13. Способ индукции клеточной адгезии гепатоцитов, при этом способ включает введение эффективного количества композиции, содержащей ANGPTL4, в популяцию гепатоцитов, таким образом индуцируя клеточную адгезию гепатоцитов.
14. Способ по п.13, в котором ANGPTL4 содержит аминокислотные остатки 23-406 ANGPTL4 человека.
15. Способ по п.13, в котором ANGPTL4 содержит аминокислотные остатки 185-406 ANGPTL4 человека.
16. Способ по п.13, в котором композиция содержит ANGPTL4 с носителем.
17. Способ ингибирования клеточной адгезии гепатоцитов, при этом способ включает
введение эффективного количества композиции, содержащей антагонист ANGPTL4, в популяцию гепатоцитов, таким образом ингибируя клеточную адгезию гепатоцитов.
18. Способ по п.17, в котором антагонистом является анти-ANGPTL4-антитело.
19. Способ по п.17, в котором антагонистом является анти- αVβ5-антитело.
20. Способ стимуляции пролиферации преадипоцитов, при этом способ включает
введение эффективного количества композиции, содержащей ANGPTL4 или агонист, в популяцию преадипоцитов, таким образом индуцируя пролиферацию преадипоцитов.
21. Способ по п.20, в котором преадипоциты находятся в организме субъекта.
22. Способ по п.20, в котором субъектом является человек.
23. Способ по п.20, в котором композиция содержит ANGPTL4 с носителем.
24. Способ по п.20, в котором ANGPTL4 содержит аминокислотные остатки 23-406 ANGPTL4 человека.
25. Способ по п.24, в котором ANGPTL4 содержит аминокислотные остатки от примерно 23 до примерно 162.
26. Способ ингибирования пролиферации преадипоцитов, при этом способ включает введение эффективного количества композиции, содержащей антагонист ANGPTL4, в популяцию преадипоцитов.
27. Способ по п.26, в котором антагонистом ANGPTL4 является анти-ANGPTL4-антитело.
28. Способ ингибирования биологической активности ANGPTL4, при этом способ включает введение антагониста ANGPTL4, который связывается с C-концом ANGPTL4.
29. Способ по п.28, в котором антагонистом ANGPTL4 является анти-ANGPTL4-антитело.
30. Способ по п.28, в котором антагонистом ANGPTL4 является анти-αVβ5-антитело.
31. Способ по п.28, в котором антагонист ANGPTL4 блокирует связывание Angptl4 с αVβ5.
32. Способ по п.28, в котором биологическая активность заключается в индукции пролиферации клеток или дифференцировки клеток.
33. Антитело, которое связывается с C-концом ANGPTL4.
34. Антитело по п.32, в котором антитело является нейтрализующим антителом.
35. Композиция, содержащая вариант ANGPTL4, при этом вариант ANGPTL4 протеолитически не процессирован.
36. Композиция по п.35, в которой вариант ANGPTL4 содержит изменение аминокислот 162 и/или 164.
37. Композиция по п.36, в которой изменение представляет собой замену.
38. Композиция по п.37, в которой замена осуществлена в положении 162 и в положении 164.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58987504P | 2004-07-20 | 2004-07-20 | |
| US60/589,875 | 2004-07-20 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009137017/10A Division RU2009137017A (ru) | 2004-07-20 | 2009-10-06 | Композиции и способы применения ангиопоэтинподобного белка 4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007106075A true RU2007106075A (ru) | 2008-08-27 |
| RU2380411C2 RU2380411C2 (ru) | 2010-01-27 |
Family
ID=35787695
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007106075/13A RU2380411C2 (ru) | 2004-07-20 | 2005-07-19 | Способ ингибирования пролиферации гепатоцитов, способ ингибирования клеточной адгезии гепатоцитов и способ ингибирования биологической активности angptl4 в гепатоцитах или предшественниках гепатоцитов |
| RU2009137017/10A RU2009137017A (ru) | 2004-07-20 | 2009-10-06 | Композиции и способы применения ангиопоэтинподобного белка 4 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009137017/10A RU2009137017A (ru) | 2004-07-20 | 2009-10-06 | Композиции и способы применения ангиопоэтинподобного белка 4 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7371384B2 (ru) |
| EP (1) | EP1781698B1 (ru) |
| JP (2) | JP5318412B2 (ru) |
| KR (1) | KR20070061524A (ru) |
| CN (1) | CN101080419B (ru) |
| AU (1) | AU2005269758B2 (ru) |
| BR (1) | BRPI0513477A (ru) |
| CA (1) | CA2574791A1 (ru) |
| DK (1) | DK1781698T3 (ru) |
| HK (1) | HK1110602A1 (ru) |
| HU (1) | HUE029170T2 (ru) |
| IL (4) | IL180752A0 (ru) |
| LT (1) | LT1781698T (ru) |
| MX (1) | MX2007000783A (ru) |
| NO (1) | NO342525B1 (ru) |
| NZ (2) | NZ552957A (ru) |
| RU (2) | RU2380411C2 (ru) |
| WO (1) | WO2006014678A2 (ru) |
| ZA (1) | ZA200701184B (ru) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| JP4947717B2 (ja) * | 2004-07-20 | 2012-06-06 | ジェネンテック， インコーポレイテッド | アンジオポエチン様４タンパク質のインヒビター、組み合わせ、およびそれらの使用 |
| RU2380411C2 (ru) | 2004-07-20 | 2010-01-27 | Дженентек, Инк. | Способ ингибирования пролиферации гепатоцитов, способ ингибирования клеточной адгезии гепатоцитов и способ ингибирования биологической активности angptl4 в гепатоцитах или предшественниках гепатоцитов |
| WO2006074228A1 (en) | 2005-01-07 | 2006-07-13 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 ) |
| WO2007024723A2 (en) * | 2005-08-19 | 2007-03-01 | Washington University In St. Louis | Methods and compositions for treating gastrointestinal radiosensitivity in a subject |
| EP2050335A1 (en) * | 2006-02-17 | 2009-04-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| CA2698812A1 (en) | 2007-09-14 | 2009-03-19 | Nitto Denko Corporation | Drug carriers |
| JP5393798B2 (ja) * | 2008-10-20 | 2014-01-22 | リポサイエンス，インコーポレイテッド | リポタンパク質インスリン抵抗性指数、ならびに同一物を生成するための関連する方法、システムおよびコンピュータプログラム |
| WO2011046515A1 (en) | 2009-10-14 | 2011-04-21 | Nanyang Technological University | Antiproliferative agent |
| WO2011085271A2 (en) | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| US20130023473A1 (en) * | 2010-01-20 | 2013-01-24 | Stephane Germain | Methods and pharmaceutical composition for the preservation of vascular endothelial cell barrier integrity |
| US9475850B2 (en) * | 2010-06-05 | 2016-10-25 | The Uab Research Foundation | Methods for treatment of nephrotic syndrome and related conditions |
| CA2801579C (en) * | 2010-06-05 | 2021-12-14 | The Uab Research Foundation | Methods for treatment of nephrotic syndrome and related conditions |
| US9139629B2 (en) | 2010-06-05 | 2015-09-22 | The Uab Research Foundation | Methods for treatment of nephrotic syndrome and related conditions |
| EP2661626B1 (en) * | 2011-01-08 | 2016-06-01 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN102692500B (zh) * | 2011-03-21 | 2015-06-10 | 上海市肿瘤研究所 | Angptl4作为血清学检测肝癌转移的标志物及其应用 |
| CN102692496B (zh) * | 2011-03-21 | 2015-10-28 | 上海市肿瘤研究所 | Angptl4作为缺氧检测的标志物及其应用 |
| CN102242198A (zh) * | 2011-05-25 | 2011-11-16 | 信阳师范学院 | 通过angptl4基因多态性进行牛育种方法 |
| EP2723758B1 (en) * | 2011-06-21 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof |
| CA2840646C (en) | 2011-07-01 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for selective regulation of protein expression |
| SG10201607346XA (en) * | 2011-08-08 | 2016-10-28 | Univ Nanyang Tech | Angiopoietin-like 4 and its use in modulating cell leakiness |
| ES2764106T3 (es) | 2011-12-09 | 2020-06-02 | Metabolic Pharmaceuticals Pty Ltd | Uso de fragmentos de la hormona del crecimiento |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| CN104822419B (zh) | 2012-07-19 | 2020-08-18 | 南洋理工大学 | 血管生成素样4及其用于伤口愈合的方法 |
| AU2014233219B2 (en) * | 2013-03-15 | 2018-02-22 | Sumant S. CHUGH | Methods for treatment of nephrotic syndrome and related conditions |
| EP2992098B1 (en) | 2013-05-01 | 2019-03-27 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating hbv and ttr expression |
| EP3021942A4 (en) | 2013-07-19 | 2017-04-19 | The Regents of The University of California | Milk fat globule epidermal growth factor 8 regulates fatty acid uptake |
| CA2931510A1 (en) | 2013-12-24 | 2015-07-02 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| WO2015123576A2 (en) * | 2014-02-17 | 2015-08-20 | The Brigham And Women's Hospital, Inc. | Targeted nanoparticle compositions and methods of their use to treat obesity |
| BR122020024443B1 (pt) | 2014-05-01 | 2022-02-22 | Ionis Pharmaceuticals, Inc | Composto e composição farmacêutica para modulação da expressão de angptl3 |
| PE20170287A1 (es) * | 2014-08-07 | 2017-04-05 | Novartis Ag | Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso |
| TW201613977A (en) | 2014-08-07 | 2016-04-16 | Novartis Ag | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use |
| CN105021827B (zh) * | 2015-07-17 | 2016-09-28 | 北京大学第一医院 | 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用 |
| PE20180465A1 (es) | 2015-07-22 | 2018-03-06 | Monsanto Technology Llc | Metodos y composiciones para la regulacion selectiva de la expresion de proteinas |
| BR122023026882A2 (pt) | 2015-11-06 | 2024-01-23 | Ionis Pharmaceuticals, Inc | Uso de um composto oligomérico |
| US20190185849A1 (en) * | 2016-06-29 | 2019-06-20 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
| EP3880819A2 (en) * | 2018-11-13 | 2021-09-22 | Lipigon Pharmaceuticals AB | Angptl4 oligonucleotides influencing the regulation of the fatty acid metabolism |
| EP4037713A4 (en) * | 2019-11-06 | 2023-11-01 | Northwestern University | INHIBITION OF PHOSPHATASE VE-PTP TO PROTECT THE KIDNEY AGAINST ISCHEMIA-REPERFUSION INJURY |
| KR20220112290A (ko) * | 2019-12-09 | 2022-08-10 | 엠피리코 인크. | 안지오포이에틴 유사 4(angptl4) 관련 질환의 치료를 위한 올리고뉴클레오타이드 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
| US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6348350B1 (en) | 1997-09-19 | 2002-02-19 | Genentech, Inc. | Ligand homologues |
| US20030207375A1 (en) | 1997-10-24 | 2003-11-06 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO1999032515A2 (en) | 1997-12-19 | 1999-07-01 | Zymogenetics, Inc. | Angiopoietin homolog, dna encoding it, and method of making it |
| WO1999045135A1 (en) | 1998-03-02 | 1999-09-10 | Millennium Pharmaceuticals, Inc. | Novel fdrg protein and nucleic acid molecules and uses therefor |
| US20030099994A1 (en) | 1998-03-02 | 2003-05-29 | Millennium Pharamceuticals, Inc. | Novel FDRG protein and nucleic acid molecules and uses therefor |
| JP2000026767A (ja) | 1998-05-01 | 2000-01-25 | Daikin Ind Ltd | 熱硬化性粉体塗料組成物 |
| AU4682999A (en) | 1998-06-16 | 2000-01-05 | Human Genome Sciences, Inc. | 94 human secreted proteins |
| AU4643699A (en) | 1998-06-24 | 2000-01-10 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
| WO2001053455A2 (en) | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| JP2000308488A (ja) | 1999-02-23 | 2000-11-07 | Herikkusu Kenkyusho:Kk | 血管新生に関連するタンパク質および該タンパク質をコードする遺伝子 |
| WO2000052165A2 (en) | 1999-03-04 | 2000-09-08 | Corixa Corporation | Compositions and methods for breast cancer therapy and diagnosis |
| ATE364628T1 (de) | 1999-03-08 | 2007-07-15 | Genentech Inc | Verfahren und zusammensetzungen zur diagnose von tumoren |
| WO2000061629A1 (en) | 1999-04-09 | 2000-10-19 | Human Genome Sciences, Inc. | 49 human secreted proteins |
| ES2265931T3 (es) | 1999-04-16 | 2007-03-01 | Genentech, Inc. | Variantes del factor de crecimiento celular endotelial vascular (vegf) y sus usos. |
| AU5979300A (en) | 1999-07-02 | 2001-01-22 | Bayer Aktiengesellschaft | Angiopoietin-6 and uses thereof |
| AU6605900A (en) | 1999-07-16 | 2001-02-05 | Hyseq, Inc. | Novel angiopoietin materials and methods |
| CA2379925A1 (en) | 1999-07-20 | 2001-01-25 | Curagen Corporation | Polypeptides and polynucleotides encoding same |
| US20030207348A1 (en) | 1999-07-20 | 2003-11-06 | Shimkets Richard A. | Polypeptides and polynucleotides encoding same |
| EP1285084A1 (en) | 2000-01-25 | 2003-02-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| AU2001243142A1 (en) | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| CN1315451A (zh) | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人血管形成素类似因子45和编码这种多肽的多核苷酸 |
| AU2001249929A1 (en) | 2000-04-07 | 2001-10-23 | Dana-Farber Cancer Institute Inc. | Fdrg proteins and nucleic acid molecules and uses therefor |
| US6673545B2 (en) | 2000-07-28 | 2004-01-06 | Incyte Corporation | Prostate cancer markers |
| CN1170850C (zh) | 2000-09-19 | 2004-10-13 | 上海市肿瘤研究所 | 人血管生成素样蛋白和编码序列及其用途 |
| US20040249141A1 (en) | 2000-10-16 | 2004-12-09 | Audrey Goddard | Tie ligand homologues |
| CA2442743A1 (en) | 2001-03-27 | 2002-12-12 | Human Genome Sciences, Inc. | Human secreted proteins |
| IL159153A0 (en) | 2001-06-08 | 2004-06-01 | Sankyo Co | Methods for testing drugs for treating or preventing diseases such as hyperlipidemia |
| WO2003010205A1 (en) * | 2001-07-26 | 2003-02-06 | Duke University Medical Center | Genes induced by hypoxia |
| JP2005518782A (ja) | 2001-09-17 | 2005-06-30 | プロテイン デザイン ラブス， インコーポレイテッド | ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法 |
| US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US20040038230A1 (en) | 2001-11-05 | 2004-02-26 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| EP1539985A4 (en) | 2001-11-05 | 2006-06-28 | Curagen Corp | THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES, AND METHODS OF USE |
| NZ532852A (en) | 2001-11-16 | 2006-08-31 | Genentech Inc | Composition comprising and method of using angiopoietin-like protein 3 Angptl3 |
| WO2003048185A2 (en) | 2001-11-30 | 2003-06-12 | Genvec, Inc. | Angiopioetin related factors |
| EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2003103581A2 (en) | 2002-06-05 | 2003-12-18 | Genentech, Inc. | Compositions and methods for liver growth and liver protection |
| US20050239706A1 (en) | 2003-10-31 | 2005-10-27 | Washington University In St. Louis | Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject |
| CA2499791A1 (en) | 2004-03-30 | 2005-09-30 | F. Hoffmann-La Roche Ag | Angptl4/fiaf as marker for ppardelta modulation |
| JP4947717B2 (ja) * | 2004-07-20 | 2012-06-06 | ジェネンテック， インコーポレイテッド | アンジオポエチン様４タンパク質のインヒビター、組み合わせ、およびそれらの使用 |
| RU2380411C2 (ru) * | 2004-07-20 | 2010-01-27 | Дженентек, Инк. | Способ ингибирования пролиферации гепатоцитов, способ ингибирования клеточной адгезии гепатоцитов и способ ингибирования биологической активности angptl4 в гепатоцитах или предшественниках гепатоцитов |
| WO2006074228A1 (en) * | 2005-01-07 | 2006-07-13 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 ) |
-
2005
- 2005-07-19 RU RU2007106075/13A patent/RU2380411C2/ru active
- 2005-07-19 EP EP05790823.8A patent/EP1781698B1/en active Active
- 2005-07-19 WO PCT/US2005/025650 patent/WO2006014678A2/en active Application Filing
- 2005-07-19 US US11/185,204 patent/US7371384B2/en active Active
- 2005-07-19 HU HUE05790823A patent/HUE029170T2/en unknown
- 2005-07-19 AU AU2005269758A patent/AU2005269758B2/en active Active
- 2005-07-19 NZ NZ552957A patent/NZ552957A/en not_active IP Right Cessation
- 2005-07-19 BR BRPI0513477-3A patent/BRPI0513477A/pt not_active Application Discontinuation
- 2005-07-19 KR KR1020077003874A patent/KR20070061524A/ko not_active Application Discontinuation
- 2005-07-19 DK DK05790823.8T patent/DK1781698T3/en active
- 2005-07-19 CN CN200580031686.XA patent/CN101080419B/zh not_active Expired - Fee Related
- 2005-07-19 MX MX2007000783A patent/MX2007000783A/es active IP Right Grant
- 2005-07-19 LT LTEP05790823.8T patent/LT1781698T/lt unknown
- 2005-07-19 ZA ZA200701184A patent/ZA200701184B/en unknown
- 2005-07-19 JP JP2007522672A patent/JP5318412B2/ja not_active Expired - Fee Related
- 2005-07-19 CA CA002574791A patent/CA2574791A1/en not_active Abandoned
-
2006
- 2006-09-28 US US11/540,430 patent/US20070054856A1/en not_active Abandoned
-
2007
- 2007-01-17 IL IL180752A patent/IL180752A0/en active IP Right Grant
- 2007-02-19 NO NO20070950A patent/NO342525B1/no not_active IP Right Cessation
-
2008
- 2008-05-02 HK HK08104828.2A patent/HK1110602A1/xx not_active IP Right Cessation
-
2009
- 2009-10-05 US US12/573,832 patent/US8633155B2/en not_active Expired - Fee Related
- 2009-10-06 RU RU2009137017/10A patent/RU2009137017A/ru not_active Application Discontinuation
-
2010
- 2010-06-20 IL IL206483A patent/IL206483A/en active IP Right Grant
- 2010-12-07 IL IL209823A patent/IL209823A0/en unknown
-
2011
- 2011-05-20 NZ NZ592973A patent/NZ592973A/xx not_active IP Right Cessation
- 2011-08-26 JP JP2011184642A patent/JP2011235179A/ja not_active Withdrawn
-
2012
- 2012-02-28 IL IL218357A patent/IL218357A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007106075A (ru) | Композиции и способы применения ангиопоэтинподобного белка 4 | |
| JP2008507531A5 (ru) | ||
| KR102657457B1 (ko) | 최적화된 활성 비율을 갖는 fgf21 화합물/glp-1r 작용제 조합물 | |
| Worster et al. | Chondrocytic differentiation of mesenchymal stem cells sequentially exposed to transforming growth factor‐β1 in monolayer and insulin‐like growth factor‐I in a three‐dimensional matrix | |
| Mukohyama et al. | The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK | |
| Kimura et al. | Controlled release of stromal-cell-derived factor-1 from gelatin hydrogels enhances angiogenesis | |
| ES2661500T3 (es) | Variantes de HMGB1 y sus usos | |
| ATE540973T1 (de) | Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung | |
| Hwang et al. | Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo | |
| DE60125381D1 (de) | Zusammensetzungen und verfahren mit analogen von g-csf | |
| JP5036546B2 (ja) | 胸腺特異的タンパク質 | |
| ATE534732T1 (de) | Molekulare targets und zusammensetzungen sowie verfahren zu deren identifikation zur behandlung von degenerations- und entzündungserkankungen | |
| JP2012515778A5 (ru) | ||
| JP2005516072A5 (ru) | ||
| ATE479763T1 (de) | Zusammensetzungen zur verbesserung der antisense- wirksamkeit und des transports von nukleinsäureanalog in zellen | |
| KR20090086066A (ko) | 당뇨성 창상 치유에 유용한 방법 및 조성물 | |
| WO2005086835A3 (en) | Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics | |
| RU2013126581A (ru) | Мутанты стрептокиназы и их ковалентно модифицированные формы | |
| MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
| FR2805821B1 (fr) | Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires | |
| ATE500266T1 (de) | Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine | |
| Takaya et al. | Interleukin-17 stimulates chemokine (interleukin-8 and monocyte chemoattractant protein-1) secretion in human pancreatic periacinar myofibroblasts | |
| EA202091496A1 (ru) | Вариант инсектицидного гена axmi115 и способы его применения | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| EA200700346A1 (ru) | Бактериофаг- и профаг-специфические протеины в генной терапии рака |